Conferences

The American Medical Association House of Delegates pledged on June 11 to advance gender equity in medicine after multiple studies highlighted the wage gap and discrimination women physicians continue to face.
An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.
Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.
May 23, 2018 | Hypertension
Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.
At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.
A sensing filter added to Boston Scientific’s Emblem subcutaneous implantable cardioverter defibrillators (S-ICDs) more than halved the number of inappropriate shocks given to patients over a one-year period, according to a real-world European study presented May 11 at the Heart Rhythm Society’s annual scientific sessions in Boston.